Advanced glycation end products impair coronary artery BK channels via AMPK/Akt/FBXO32 signaling pathway

Diab Vasc Dis Res. 2023 Jul-Aug;20(4):14791641231197107. doi: 10.1177/14791641231197107.

Abstract

Background: Advanced glycation end products (AGEs) impair vascular physiology in Diabetes mellitus (DM). However, the underlying mechanisms remain unclear. Vascular large conductance calcium-activated potassium (BK) channels play important roles in coronary arterial function.Purpose: Our study aimed to investigate the regulatory role of AGEs in BK channels.Research Design: Using gavage of vehicle (V, normal saline) or aminoguanidine (A) for 8 weeks, normal and diabetic rats were divided into four groups: C+V group, DM+V group, C+A group, and DM+A group.Study Sample: Coronary arteries from different groups of rats and human coronary smooth muscle cells were used in this study.Data Collection and Analysis: Data were presented as mean ± SEM (standard error of mean). Student's t-test was used to compare data between two groups. One-way ANOVA with post-hoc LSD analysis was used to compare data between multiple groups.Results: Compared to the C+V group, vascular contraction induced by iberiotoxin (IBTX), a BK channel inhibitor, was impaired, and BK channel densities decreased in the DM+V group. However, aminoguanidine administration reduced the impairment. Protein expression of BK-β1, phosphorylation of adenosine 5'-monophosphate-activated protein kinase (AMPK), and protein kinase B (PKB or Akt) were down-regulated, while F-box protein 32 (FBXO32) expression increased in the DM+V group and in high glucose (HG) cultured human coronary smooth muscle cells. Treatment with aminoguanidine in vitro and in vivo could reverse the above protein expression. The effect of aminoguanidine on the improvement of BK channel function by inhibiting the generation of AGEs was reversed by adding MK2206 (Akt inhibitor) or Compound C (AMPK inhibitor) in HG conditions in vitro.Conclusions: AGEs aggravate BK channel dysfunction via the AMPK/Akt/FBXO32 signaling pathway.

Keywords: Advanced glycation end products; F-box protein 32; adenosine monophosphate activated protein kinase; diabetes mellitus; large conductance calcium activated potassium channel; protein kinase B.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • AMP-Activated Protein Kinases / pharmacology
  • Animals
  • Coronary Vessels* / metabolism
  • Diabetes Mellitus, Experimental* / chemically induced
  • Diabetes Mellitus, Experimental* / drug therapy
  • Diabetes Mellitus, Experimental* / metabolism
  • Glycation End Products, Advanced / metabolism
  • Guanidines
  • Humans
  • Large-Conductance Calcium-Activated Potassium Channels / metabolism
  • Large-Conductance Calcium-Activated Potassium Channels / pharmacology
  • Muscle Proteins / metabolism
  • Muscle Proteins / pharmacology
  • Myocytes, Smooth Muscle
  • Proto-Oncogene Proteins c-akt / metabolism
  • Rats
  • SKP Cullin F-Box Protein Ligases / metabolism
  • SKP Cullin F-Box Protein Ligases / pharmacology
  • Signal Transduction

Substances

  • Large-Conductance Calcium-Activated Potassium Channels
  • AMP-Activated Protein Kinases
  • Proto-Oncogene Proteins c-akt
  • Glycation End Products, Advanced
  • Muscle Proteins
  • SKP Cullin F-Box Protein Ligases
  • pimagedine
  • Guanidines
  • FBXO32 protein, human